ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: PP01

From Diagnosis to the Establishment of the Labalaba Foundation: My Journey from Surviving to Thriving

Chisa Nosamiefan1, Courtnie Phillip 2 and Candace Feldman 2, 1The Labalaba Foundation, 2Brigham and Women's Hospital, Massachusetts

Meeting: 2019 ACR/ARP Annual Meeting

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: Patient Perspectives Poster Session

Session Type: Poster Session (Sunday)

Session Time: 11:30AM-1:30PM

Background/Purpose: After having my youngest son in 1994, I developed discomfort in my fingers which I ignored. In 1997, I had pericarditis, and two years later, pleurisy. I was diagnosed with lupus at the Cleveland Hospital in Florida about 20 years ago, 4-5 years after my initial symptoms. My initial treatment was inconsistent, because I lived 4 hours away from the healthcare facility, and I did not have adequate health insurance. At this time, my symptoms were frequent fevers, weight loss, abdominal pain, and generalized myalgias. I took acetaminophen or naproxen and medicines like Zantac for the abdominal pain.

Treatment: I moved to Boston in 2008 and I started a consistent treatment regimen: prednisone, hydroxychloroquine, omeprazole, azathioprine, lisinopril, nifedipine. My disease also progressed. I experienced increased myalgias and developed blood clots and pulmonary hypertension. I continued to experience pericarditis and pleurisy. I was switched from azathioprine to mycophenolate mofetil, and warfarin and gabapentin were added. Abatacept was tried for my joints but I developed a rash. I was switched to belimumab.. Finding the right cocktail of drugs required the masterful skill of my healthcare team to move me from barely surviving with lupus, and now, well on the way to thriving despite lupus.

Maintenance: After setbacks to my health between 2008-2015 (falls, increased pain, hospitalizations, difficulty coping, and having to stop work) I began to improve. I earned my master’s degree and started a consulting practice. I became active again with my Christian ministry and my stress level lessened, which seemed to be tied to reduced lupus activity. As a woman of Nigerian descent, it occurred to me that I had never met another Nigerian living with lupus. If lupus is prevalent in people of African descent in the US then it must be present in Africa and in Nigeria, the most populous African nation. I embarked on a fact finding trip and then started The Labalaba Foundation for Lupus Awareness and Advocacy in Nigeria. I also began to participate in Boston-based research studies and became a member of the Patient Advisory Board of the largest lupus center in New England.

Quality of Life: My quality of life has drastically improved over the past three years. I am more active at home, I have socially re-engaged, I go shopping, and I travel. For many years I was unable to do this. Most amazing is that I am now a lupus advocate, educator and champion. Since I began helping lupus patients I have not been hospitalized. Lupus is a complex disease and the complexity goes beyond the clinical symptomatic manifestations. Each lupus manifestation is influenced by a patient’s social circumstances and access to good medical care. The health and wellbeing of lupus patients may improve when definite steps are taken to address stress factors and other lifestyle triggers. Through my own journey and the creation of The Labalaba Foundation, I have taken charge of my health and hope to help others do the same.

Figure 1

Timeline of my journey with lupus, from my initial symptoms until the present time

Figure 2

The Labalaba Foundation for Lupus Awareness and Advocacy programs and initiatives

Image 1

Chisa Nosamiefan, patient and founder of The Labalaba Foundation, pictured with Labalaba Champions in Nigeria


Disclosure: C. Nosamiefan, None; C. Phillip, None; C. Feldman, None.

To cite this abstract in AMA style:

Nosamiefan C, Phillip C, Feldman C. From Diagnosis to the Establishment of the Labalaba Foundation: My Journey from Surviving to Thriving [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/from-diagnosis-to-the-establishment-of-the-labalaba-foundation-my-journey-from-surviving-to-thriving/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/from-diagnosis-to-the-establishment-of-the-labalaba-foundation-my-journey-from-surviving-to-thriving/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology